Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             579 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 17AAG low target binding affinity and potent whole cell potency: finding an explanation 2002
 38 S7 p. S64-
1 p.
 artikel
2 Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo 2002
 38 S7 p. S139-S140
2 p.
 artikel
3 Absence of vascular regrowth at 96hrs in response to the vascular-targeting agent ZD6126 demonstrated by dynamic-contrast enhanced (DCE) MRI 2002
 38 S7 p. S37-
1 p.
 artikel
4 ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFr) monoclonal antibody: phase II clinical trial in renal cell cancer (RCC) 2002
 38 S7 p. S57-
1 p.
 artikel
5 A calicheamicin conjugate that targets LewisY selectively destroys LewisY-positive human carcinoma cells and xenografts 2002
 38 S7 p. S150-S151
2 p.
 artikel
6 A clinical phase I and biomarker study of the Raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumors 2002
 38 S7 p. S53-S54
2 p.
 artikel
7 A combinatorial chemistry approach to gene targeting agents 2002
 38 S7 p. S14-
1 p.
 artikel
8 A concise synthetic route to C2-endo/exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepines(PBDs) with potent in vitro cytotoxicity 2002
 38 S7 p. S124-S125
2 p.
 artikel
9 Activation of c-Jun-N-terminal-kinase by R- and S-flurbiprofen results in cell cycle arrest in human colon carcinoma cells 2002
 38 S7 p. S51-
1 p.
 artikel
10 Activation of Fas-mediated apoptosis in 5-fluorouracil treated breast and colorectal cancer cell lines 2002
 38 S7 p. S168-
1 p.
 artikel
11 Activation of wt p53 protein in normal and tumor cells by a novel anti-cancer drug CHS 828 2002
 38 S7 p. S109-
1 p.
 artikel
12 Active and protective immunity induced by a protein based vaccine targeting the HER2/neu oncogenic protein 2002
 38 S7 p. S138-
1 p.
 artikel
13 Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR [KDR]-TKI), in a model of ZD1839 (‘Iressa’) resistance 2002
 38 S7 p. S60-S61
2 p.
 artikel
14 Additive interaction of platinum compounds and 17-AAG in colon cancer cell lines depends on intact JNK signaling 2002
 38 S7 p. S60-
1 p.
 artikel
15 Additive/synergistic interaction between MKP-1 inhibitors and anti-cancer drugs in human non-small-cell lung cancer cell H292 2002
 38 S7 p. S107-
1 p.
 artikel
16 Administration of FGF-2 peptide vaccine leads to abrogation of angiogenesis and tumor development 2002
 38 S7 p. S137-S138
2 p.
 artikel
17 A high-throughput fluorescent anisotropy screen to identify small molecules that inhibit AP-1 binding to DNA 2002
 38 S7 p. S133-
1 p.
 artikel
18 A high throughput screening for p21Waf1/Cip1 protein expression using Fluorometric Microvolume Assay Technology (FMAT) 2002
 38 S7 p. S134-
1 p.
 artikel
19 AKT as a target for enhancing breast cancer chemotherapy and radiotherapy 2002
 38 S7 p. S159-
1 p.
 artikel
20 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2 2002
 38 S7 p. S118-
1 p.
 artikel
21 alpha2-6-sialylated neolacto-series gangliosides serve as receptors for the anticancer drug rViscumin 2002
 38 S7 p. S107-S108
2 p.
 artikel
22 A molecular overlap tool for investigating potential binding mode similarity in sets of compounds 2002
 38 S7 p. S135-
1 p.
 artikel
23 A multicenter, phase I/II trial of hepatic intra-arterial delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in patients with hepatocellular carcinoma 2002
 38 S7 p. S18-
1 p.
 artikel
24 Analysis of biomarkers in response to FB642 in human neuroblastoma cells in vitro 2002
 38 S7 p. S38-S39
2 p.
 artikel
25 Analysis of in vitro and in vivo activity of a newly synthesized psorospermin analog 2002
 38 S7 p. S31-
1 p.
 artikel
26 Analysis of the expression of 90K/Mac-2 binding protein (M2BP) in lung cancer and generation of cytotoxic T lymphocytes that recognize M2BP with an HLA-A2 restriction 2002
 38 S7 p. S139-
1 p.
 artikel
27 A new Tc-99m labelled somatostatin analogue (Tc-99m EDDA-TRYCINE-HYNIC-TOC) for receptor imaging: first clinical results before and during radioreceptor therapy with Y-90 DOTATOC 2002
 38 S7 p. S148-
1 p.
 artikel
28 An integrated approach to the pharmacogenomics and pharmacoproteomics of cancer 2002
 38 S7 p. S94-S95
2 p.
 artikel
29 A novel anti-angiogenic/anti-metastatic peptide, ATN-161 (Ac-PHSCN-NH2), which targets multiple fully activated integrins including alpha-5 beta-1 and alpha-v beta-3, leads to increased anti-tumor activity and increased survival in multiple tumor models when combined with chemotherapy 2002
 38 S7 p. S79-
1 p.
 artikel
30 A novel class of cdc25 phosphatase inhibitors shows potent anticancer activity by blocking cell cycle and inducing apoptosis 2002
 38 S7 p. S50-S51
2 p.
 artikel
31 A novel class of pyridopyrimidine tyrosine kinase inhibitors blocks cancer cells in the S-phase of the cell cycle 2002
 38 S7 p. S50-
1 p.
 artikel
32 A novel human P450 reductase activated indolequinone prodrug for use in adenoviral mediated hypoxia selective gene therapy 2002
 38 S7 p. S147-
1 p.
 artikel
33 A novel mechanism of potentiation of trail-induced apoptosis: resveratrol sensitizes resistant tumor cells for TRAIL by p21-mediated G1 arrest 2002
 38 S7 p. S153-
1 p.
 artikel
34 A novel target for antifolates: the dihydrofolate reductase domain of the G1/S transit controlling protein elF-5A 2002
 38 S7 p. S105-
1 p.
 artikel
35 A novel tumor targeting telomerase inhibitor depletes cellular atp and inhibits human prostate tumor xenograft growth in nude mouse and enhances the radiosensitivity of cultured human prostate and brain tumor cells 2002
 38 S7 p. S124-
1 p.
 artikel
36 A novel whole cell histone deactylase (HDAC) activity assay for the identification of small molecule HDAC inhibitors 2002
 38 S7 p. S121-
1 p.
 artikel
37 Ansamycins inactivate AKT and enhances the anti-tumor effects of paclitaxel 2002
 38 S7 p. S58-
1 p.
 artikel
38 Anti-angiogenic activity of the VEGF receptor tyrosine kinase inhibitor ZD6474 2002
 38 S7 p. S81-
1 p.
 artikel
39 Antiangiogenic and antitumoral activity of novel heparin derivatives 2002
 38 S7 p. S73-
1 p.
 artikel
40 Antiangiogenic potential of the novel camptothecin ST1481 2002
 38 S7 p. S47-
1 p.
 artikel
41 Anticancer activity of a 6-base length phosphodiester oligonucleotide, Oligomodulator™BT 99-25, against lymphoma 2002
 38 S7 p. S168-S169
2 p.
 artikel
42 Anti-EGFR monoclonal antibody cetuximab binds the EGFR variant III receptor and internalizes phosphorylated receptor on the cell surface 2002
 38 S7 p. S149-
1 p.
 artikel
43 Antisense oligonucleotides targeting ceramide glycosylation overcome multidrug resistance in cancer cells 2002
 38 S7 p. S142-
1 p.
 artikel
44 Antisense to a novel, hepatocyte growth factor-induced and cancer cell-specific mRNA inhibits carcinoma cell migration 2002
 38 S7 p. S144-
1 p.
 artikel
45 Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (trail) gene 2002
 38 S7 p. S143-
1 p.
 artikel
46 Antitumor activity and I-124 pet imaging based on tumor-localized salmonella 2002
 38 S7 p. S143-
1 p.
 artikel
47 Antitumor activity of g3139 (Genasense™) plus dacarbazine against human melanoma is superior to G3139 alone 2002
 38 S7 p. S145-
1 p.
 artikel
48 Antitumor activity of the EGFR/TK inhibitor Tarceva™ (erlotinib, OSI-774) in tumor models 2002
 38 S7 p. S63-S64
2 p.
 artikel
49 Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts 2002
 38 S7 p. S62-
1 p.
 artikel
50 A pharmacogenomics strategy for validation of cancer therapeutics using murine xenograph models 2002
 38 S7 p. S95-
1 p.
 artikel
51 A pharmacokinetic (PK) phase I (PI) study of ZD9331 and carboplatin in relapsed ovarian cancer (ROC) with a pharmacodynamic (PD) endpoint 2002
 38 S7 p. S24-
1 p.
 artikel
52 A phase 1 and pharmacodynamic study of PX-12, a thioredoxin inhibitor, in advanced malignancies 2002
 38 S7 p. S170-
1 p.
 artikel
53 A phase 1 and pharmacokinetic study of TAS-106 administered weekly for 3 consecutive weeks every 28 days in patients with solid tumors 2002
 38 S7 p. S25-
1 p.
 artikel
54 A phase I and pharmacokinetic study of BB10901, a maytansinoid immunoconjugate, in CD56 expressing tumors 2002
 38 S7 p. S152-S153
2 p.
 artikel
55 A phase I and pharmacokinetic study of DE-310 administered as a 3 hour infusion every 4 weeks (wks) to patients (pts) with advanced solid tumors or lymphomas 2002
 38 S7 p. S46-
1 p.
 artikel
56 A phase I and pharmacokinetic study of the farnesyl transferase inhibitor, CP-609,754 in patients with advanced solid tumors 2002
 38 S7 p. S56-
1 p.
 artikel
57 A phase I clinical and pharmacokinetic (PK) study with KahalalideF (KF) in patients (pts) with advanced solid tumors (AST) with a continuous weekly (W) 1-hour iv infusion schedule 2002
 38 S7 p. S33-
1 p.
 artikel
58 A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) 2002
 38 S7 p. S88-
1 p.
 artikel
59 A phase I dose escalating study of the angiogenesis inhibitor thrombospondin-1 mimetic (abt-510) in patients with advanced cancer 2002
 38 S7 p. S78-S79
2 p.
 artikel
60 A phase I, double-blind, randomized, placebo-controlled study to investigate the safety tolerability and pharmacokinetic profile of S-3304, a matrix metalloproteinase inhibitor, when given in multiple doses with high doses for 4 weeks to healthy volunteers 2002
 38 S7 p. S81-S82
2 p.
 artikel
61 A phase I/II study of DX-8951f and gemcitabine in advanced solid tumour malignancies 2002
 38 S7 p. S46-S47
2 p.
 artikel
62 A phase I/II vaccination study of patients with minimal residual prostatic adenocarcinoma after radical prostatectomy using autologous dendritic cells pulsed with recombinant PSA (Elademtm) 2002
 38 S7 p. S136-
1 p.
 artikel
63 A Phase II Study of ANGIOZYME® in combination with 5-fluorouracil, leucovorin and ironotecan in the treatment of metastatic colorectal cancer patients 2002
 38 S7 p. S72-
1 p.
 artikel
64 A phase II study of Erbitux (IMC-C225), an Epidermal Growth Factor Receptor (EGFR) blocking ntibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced Non-Small Cell Lung Cancer (NSCLC) 2002
 38 S7 p. S153-
1 p.
 artikel
65 A phase II study of MEN-10755 in patients with advanced or metastatic ovarian cancer 2002
 38 S7 p. S18-
1 p.
 artikel
66 A phase II trial of an attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant dysplastic oral lesions 2002
 38 S7 p. S84-
1 p.
 artikel
67 A phase II trial of etanercept, a tumour necrosis factor-a inhibitor in recurrent ovarian cancer 2002
 38 S7 p. S140-
1 p.
 artikel
68 A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR 2002
 38 S7 p. S69-S70
2 p.
 artikel
69 A phase I pharmacokinetic study of ONT-093 in combination with paclitaxel in patients with advanced cancer 2002
 38 S7 p. S156-
1 p.
 artikel
70 A phase I study of fenretinide combined with paclitaxel and cisplatin for the treatment of refractory solid tumors 2002
 38 S7 p. S20-
1 p.
 artikel
71 A phase I study of Ro 31-7453, a novel oral cell cycle inhibitor, in combination with paclitaxel: final results 2002
 38 S7 p. S49-
1 p.
 artikel
72 A phase I study of S-3304 a matrix metalloproteinase inhibitor in patients with solid tumors 2002
 38 S7 p. S77-
1 p.
 artikel
73 A phase I study of the heparanase inhibitor PI-88 given subcutaneously (sq) in patients (pts) with advanced solid malignancies 2002
 38 S7 p. S74-S75
2 p.
 artikel
74 A phase I study of the novel high affinity VEGF blocker VEGF trap in patients with refractory solid tumors and lymphoma 2002
 38 S7 p. S81-
1 p.
 artikel
75 A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer 2002
 38 S7 p. S77-
1 p.
 artikel
76 A phase I study of TNP-470 continuous infusion alone or in combination with paclitaxel and carboplatin in adult patients with non small cell lung cancer (NSCLC) and other solid tumors 2002
 38 S7 p. S79-
1 p.
 artikel
77 A phase I study of weekly BMS-214662, a novel farnesyl:protein transferase inhibitor, combined with weekly paclitaxel 2002
 38 S7 p. S55-
1 p.
 artikel
78 A phase I study of ZD 1839 (lressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies 2002
 38 S7 p. S63-
1 p.
 artikel
79 A phase I trial assessing the pharmacokinetics and tolerability of ZD1839 (‘Iressa’) in hepatically impaired patients with solid tumours 2002
 38 S7 p. S55-S56
2 p.
 artikel
80 A phase I trial of ABT-751, a novel microtubulin inhibitor 2002
 38 S7 p. S42-
1 p.
 artikel
81 A phase I trial of 17-Allyl-Amino-Geldanamycin (17-AAG) in patients with advanced cancer 2002
 38 S7 p. S54-S55
2 p.
 artikel
82 A phase 1 trial of the sulfonylhydrazine prodrug VNP40101M, a novel alkylating agent for the treatment of cancer 2002
 38 S7 p. S27-
1 p.
 artikel
83 Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta 2002
 38 S7 p. S165-
1 p.
 artikel
84 Apoptosis signaling by 2-methoxyestradiol in DS-sarcoma cells 2002
 38 S7 p. S169-
1 p.
 artikel
85 Apoptotic pathways and novel activity of the epothilone B analog bms-310705 in human non-small cell lung carcinoma (NSCLC) 2002
 38 S7 p. S40-
1 p.
 artikel
86 Apoptotic response and the mechanism of resistance to camptothecin: a study of gene expression and functional effects 2002
 38 S7 p. S165-
1 p.
 artikel
87 Application of combinatorial chemistry for the identification of pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase 2002
 38 S7 p. S118-
1 p.
 artikel
88 Approaches to structure-based drug discovery for the HSP-90 family 2002
 38 S7 p. S101-
1 p.
 artikel
89 A protein containing the DHHC domain is upregulated in ovarian carcinomas 2002
 38 S7 p. S101-
1 p.
 artikel
90 A ribozyme-based gene therapy approach to target the survivin pathway in human prostate cancer cells 2002
 38 S7 p. S147-
1 p.
 artikel
91 A-ring analogues of oestrone 3-O-sulphamate as potent steroid sulphatase inhibitors and potential anti-cancer agents 2002
 38 S7 p. S125-
1 p.
 artikel
92 A role for over-expressed human cytosolic NOS-II in the bioactivation and toxicity of tirapazamine in vitro 2002
 38 S7 p. S20-
1 p.
 artikel
93 Aspirin induces b-catenin phosphorylation and reduces expression of Akt/PKB 2002
 38 S7 p. S59-
1 p.
 artikel
94 A strategy for identification of gene targets by integrating genome and transcriptome data in cancer 2002
 38 S7 p. S100-
1 p.
 artikel
95 Author index 2002
 38 S7 p. S175-S188
14 p.
 artikel
96 5-aza-2′-deoxycytidine and Trichostathin A enhanced growth inhibitory effect of all trans retinoic acid by the restoration of retinoic acid receptor β expression in head and neck squamous carcinoma cells 2002
 38 S7 p. S85-S86
2 p.
 artikel
97 Bcl-2 overexpression inhibits TRAIL-induced apoptosis in type II cells 2002
 38 S7 p. S164-
1 p.
 artikel
98 bcl-2 specific siRNA molecules inhibit growth of pancreatic cancer in vitro and in vivo 2002
 38 S7 p. S142-S143
2 p.
 artikel
99 2-Benzimidazolylhydrazones derived from alpha-(N)-acyl heteroaromatics: RNA synthesis inhibitors with camptothecin-like activity 2002
 38 S7 p. S127-
1 p.
 artikel
100 Beta-adrenergic, AA-dependent pathways as targets for chemoprevention of pulmonary and pancreatic adenocarcinoma 2002
 38 S7 p. S87-
1 p.
 artikel
101 Biological and therapeutic properties of a novel, fully human monoclonal antibody targeting prostate specific membrane antigen 2002
 38 S7 p. S152-
1 p.
 artikel
102 Biology of ErbB/HER receptors 2002
 38 S7 p. S4-
1 p.
 artikel
103 Biomarkers of anticancer activity of R115777 in combination with paclitaxel in a human breast cancer model in vitro 2002
 38 S7 p. S58-
1 p.
 artikel
104 Biomarkers of in vitro response to HMN-176 in human ovarian cell lines 2002
 38 S7 p. S40-S41
2 p.
 artikel
105 Biomarkers of in vivo response to BCL-2 antisense in human prostate cancer xenografts 2002
 38 S7 p. S145-S146
2 p.
 artikel
106 Biomarkers (VEGF, BFGF) for assessing the biological activity of PTK787/zk222584 (PTK/ZK), a vascular endothelial growth factor (VEGF) receptor inhibitor, in tumours known to overexpress VEGF 2002
 38 S7 p. S78-
1 p.
 artikel
107 Bleomycin combinatorial libraries: a strategy for identifying mechanism of action and improved analogues 2002
 38 S7 p. S13-S14
2 p.
 artikel
108 Blockade of endothelin A receptor by ABT 627 suppresses tumor growth, neovascularization and potentiates cytotoxic paclitaxel activity in ovarian cancer cells in vitro and in vivo 2002
 38 S7 p. S99-S100
2 p.
 artikel
109 BNP7787 as a potential protector of cisplatin-induced side-effects: step-wise reduction of the hydration schedule 2002
 38 S7 p. S48-
1 p.
 artikel
110 Brostallicin potentates the antitumor activity of other cytotoxic antineoplastic agents in experimental tumor models 2002
 38 S7 p. S29-
1 p.
 artikel
111 Cancer therapy based on p53 and Rb 2002
 38 S7 p. S116-
1 p.
 artikel
112 Cancer vaccines based on defined tumor antigens: specificity with an eye on prevention 2002
 38 S7 p. S9-
1 p.
 artikel
113 Carbohydrate mimics bind to tumour cell surfaces and inhibit cell adhesion 2002
 38 S7 p. S110-S111
2 p.
 artikel
114 Cassette dosing iv and ip of novel DNA dependent protein kinase inhibitors 2002
 38 S7 p. S160-
1 p.
 artikel
115 CB300919, a quinazoline-based antitumor agent with high activity in the CH1 human ovarian tumour xenograft 2002
 38 S7 p. S18-
1 p.
 artikel
116 CDC25 phosphatases and checkpoint controls 2002
 38 S7 p. S116-
1 p.
 artikel
117 Cell cycle arresting and apoptosis-inducing activity of mycobacterial cell wall-DNA complex (MCC) towards human bladder cancer cells 2002
 38 S7 p. S168-
1 p.
 artikel
118 Cell cycle perturbations and apoptosis induced by the novel marine compound variolin B 2002
 38 S7 p. S33-
1 p.
 artikel
119 Cellular accumulation of cisplatin is mediated by the ubiquitously expressed sodium-dependent human ASCT1-amino acid transporter 2002
 38 S7 p. S96-
1 p.
 artikel
120 Cellular and animal pharmacology of isophosphoramide mustard (IPM) 2002
 38 S7 p. S28-
1 p.
 artikel
121 Cellular and molecular markers of metastatic potential as targets for micrometastasis detection in gastrointestinal cancer 2002
 38 S7 p. S51-S52
2 p.
 artikel
122 Cellular pharmacology of PNU-159682, a liver microsomal metabolite of methoxymorpholinyl doxorubicin (Nemorubicin; MMDX) 2002
 38 S7 p. S19-
1 p.
 artikel
123 Cellular responses to DNA topoisomerase I poisons and the TOR kinase inhibitor, rapamycin 2002
 38 S7 p. S63-
1 p.
 artikel
124 Cetuximab (C225, Erbitux) in combination with irinotecan, infusional 5-fluorouracil (5-FU) and folinic acid (FA) is safe and active in patients (pts) with metastatic colorectal cancer (CRC) expressing epidermal growth factor-receptor (EGFR). Results of a phase I study 2002
 38 S7 p. S148-S149
2 p.
 artikel
125 Characterisation of CA-IX expression and activity in human tumour cell lines 2002
 38 S7 p. S102-
1 p.
 artikel
126 Characterisation of the hollow fibre assay for the determination of tubulin interaction in vivo 2002
 38 S7 p. S39-
1 p.
 artikel
127 Characterisation of the roles of Topoisomerase I and II in the mechanism of action of novel anti-tumour agents XR11576 (MLN576) and XR5944 (MLN944) 2002
 38 S7 p. S31-
1 p.
 artikel
128 Characteristics of novel non-hydroxamate inhibitors of histone deacetylases 2002
 38 S7 p. S100-
1 p.
 artikel
129 Characterization of the intracellular mechanisms behind the cytotoxic effect of the immunotoxin, 425.3-PE in two breast cancer cell lines 2002
 38 S7 p. S151-S152
2 p.
 artikel
130 Chemotherapy and chemoprevention: two currencies or two sides of the same coin? 2002
 38 S7 p. S67-
1 p.
 artikel
131 Chromosome structural changes in human cancer and their reversal by DNA methylation inhibitors 2002
 38 S7 p. S115-
1 p.
 artikel
132 CHS 828 inhibits the activity of the IkBβ kinase in vitro and the transcriptional activity of NF-kB in the human monocytic leukaemia THP-1 cells 2002
 38 S7 p. S61-
1 p.
 artikel
133 Cks1, a subunit of cyclin-dependent kinases, as a novel target for the treatment of colon cancer 2002
 38 S7 p. S51-
1 p.
 artikel
134 Claudin-1 induced apoptosis in breast tumor spheroids 2002
 38 S7 p. S162-S163
2 p.
 artikel
135 Cloning of tumor metastasis associated cDNA fragments (est)in human lung giant cell carcinoma 2002
 38 S7 p. S93-
1 p.
 artikel
136 CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of non-hodgkin's lymphoma 2002
 38 S7 p. S150-
1 p.
 artikel
137 CNTO 95, a fully human monoclonal antibody to integrins alpha v β3 and alpha v β5 has direct anti-tumor and antiangiogenic activity 2002
 38 S7 p. S77-
1 p.
 artikel
138 Co-dominance of cisplatin resistance in somatic cell hybrids 2002
 38 S7 p. S156-S157
2 p.
 artikel
139 Combination of IDN5390, an orally active taxane, with paclitaxel in a human tumor xenograft: improvement in antitumor efficacy without increase of toxicity 2002
 38 S7 p. S43-
1 p.
 artikel
140 Combination of novel sulfonamide anticancer drug, E7070, with CPT-11 “antitumor effect and synergistic mechanism” 2002
 38 S7 p. S17-S18
2 p.
 artikel
141 Combination of the heat shock protein 90 (HSP90) chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) and conventional cytotoxic agents in an ovarian cancer cell line model 2002
 38 S7 p. S52-
1 p.
 artikel
142 Combination of troxacitabine (troxatyltm) and cytosine arabinoside is beneficial in human leukemia cells 2002
 38 S7 p. S22-
1 p.
 artikel
143 Combination therapy with anti-angiogenic agents and radiotherapy 2002
 38 S7 p. S10-
1 p.
 artikel
144 Combination therapy with ZD1839 (‘Iressa’) and docetaxel in patients with advanced or metastatic non-small-cell lung cancer (nsclc): preliminary safety results of an open-label, pilot trial 2002
 38 S7 p. S55-
1 p.
 artikel
145 Combination with a bcr-directed antisense oligonucleotide synergistically improves the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropyl-ammonium in chronic myeloid leukemia cell lines 2002
 38 S7 p. S147-
1 p.
 artikel
146 Combinatorial blockade of cancer targets using inhibitors of the HSP90 molecular chaperone 2002
 38 S7 p. S71-
1 p.
 artikel
147 Combinatorial methods for identifying antitumour kinase inhibitors 2002
 38 S7 p. S13-
1 p.
 artikel
148 Combined expression of pTa and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis 2002
 38 S7 p. S106-
1 p.
 artikel
149 Combining kinase inhibitors with chemotherapy 2002
 38 S7 p. S3-
1 p.
 artikel
150 Comparisons between the behaviour of prodrugs and pro-prodrugs in Gene-directed enzyme prodrug therapy (GDEPT) with carboxypeptidase G2 (CPG2) 2002
 38 S7 p. S122-
1 p.
 artikel
151 Complex pattern of molecular targets for antineoplastic pteridines 2002
 38 S7 p. S123-
1 p.
 artikel
152 Comprehensive analysis of epidemiology and clinical significance of egfr amplification and overexpression using a multi-step tissue microarray (TMA) approach 2002
 38 S7 p. S61-
1 p.
 artikel
153 Conserved mechanism of CDC45 function in protecting yeast and human cells from DNA damage 2002
 38 S7 p. S47-
1 p.
 artikel
154 Cooperating mutations as targets for therapy in leukemia 2002
 38 S7 p. S70-
1 p.
 artikel
155 Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1 2002
 38 S7 p. S49-
1 p.
 artikel
156 Correlation between NF-kB activity and IkB degradation in tumor cells using bioluminescent reporters 2002
 38 S7 p. S97-
1 p.
 artikel
157 Covalent binding of the acronycine derivative S23906-1 to glutathione prevents DNA alkylation and reduces cytotoxicity 2002
 38 S7 p. S30-
1 p.
 artikel
158 COX-2 inhibition may not be related with growth inhibition and cell cycle phase-specific apoptosis by celecoxib in human NSCLC cells in vitro 2002
 38 S7 p. S86-
1 p.
 artikel
159 COX-inhibitors and radiation 2002
 38 S7 p. S10-
1 p.
 artikel
160 COX189 (PrexigeTM), a novel, selective cyclooxygenase-2 inhibitor, totally inhibits formation of intestinal polyps in C57BL/6J-APCmin mouse model of human adenomatous polyposis coli, and reduces neovascularization in vivo 2002
 38 S7 p. S84-
1 p.
 artikel
161 CRE-enhancer DNA decoy as a tumor target-based genetic tool to treat cancer 2002
 38 S7 p. S144-
1 p.
 artikel
162 CT-32228: a lysophosphatidic acid acyltransferase-beta (LPAAT-b) inhibitor, induces apoptosis in a variety of solid tumor, leukemia and lymphoma cell lines, but not in normal cells 2002
 38 S7 p. S96-
1 p.
 artikel
163 CT-32228, a specific inhibitor of lysophosphatidic acid acyltransferase-beta (LPAT-b) causes selective tumor cell apoptosis 2002
 38 S7 p. S69-
1 p.
 artikel
164 Cyclic AMP inhibits caspase-8-mediated, pH-dependent, apoptosis by attenuating cellular acidification 2002
 38 S7 p. S169-
1 p.
 artikel
165 Cyclin D1 and cancer 2002
 38 S7 p. S115-S116
2 p.
 artikel
166 Cytochrome P450 3A4 mediates transformation of methoxymorpholinyl doxorubicin (Nemorubicin; MMDX) to its highly potent metabolite PNU-159682 in human liver microsomes 2002
 38 S7 p. S19-
1 p.
 artikel
167 Cytochrome P450 1B1 (CYP1B1) is expressed in human colon adenocarcinomas, but its expression is not limited to the malignant epithelial cells 2002
 38 S7 p. S111-S112
2 p.
 artikel
168 Cytoplasmic re-localization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by Akt-mediated phosphorylation in breast cancer 2002
 38 S7 p. S48-
1 p.
 artikel
169 Cytotoxic indolequinones as NQO1-directed tumour-specific bioreductive prodrugs 2002
 38 S7 p. S133-
1 p.
 artikel
170 D-82318 — a new, synthetic, low molecular weight tubulin inhibitor with potent in vivo antitumor activity 2002
 38 S7 p. S38-
1 p.
 artikel
171 Defending genome integrity during S-phase: role of the Bloom's syndrome helicase 2002
 38 S7 p. S117-
1 p.
 artikel
172 Defining the biologically active dose for PTK787/ZK222584 (ptk/zk), a vascular endothelial growth factor (VEGF) receptor inhibitor, based on the assessment of two biomarkers [dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), plasma VEGF] in two phase I studies 2002
 38 S7 p. S75-
1 p.
 artikel
173 Delivery of a c-raf antisense oligodeoxynucleotide (LErafAON) by intermittent bolus dosing (weekly infusions) in patients with advanced solid tumors: a phase I study 2002
 38 S7 p. S142-
1 p.
 artikel
174 Dendritic cell therapy, clinical and histological aspects 2002
 38 S7 p. S9-
1 p.
 artikel
175 Design and biological evaluation of new fluoroquinolones with a dual mechanism of action against topoisomerase II and G-quadruplex 2002
 38 S7 p. S31-S32
2 p.
 artikel
176 Design and optimization of topoisomerase poison conjugates of triple helix-forming oligonucleotides for sequence-specific DNA cleavage 2002
 38 S7 p. S125-
1 p.
 artikel
177 Design and synthesis of prodrugs of thymidine phosphorylase inhibitors for xanthine oxidase biotransformation 2002
 38 S7 p. S122-S123
2 p.
 artikel
178 Design of a DNA damaging molecule “programmed” to release multiple high affinity inhibitors of EGFR tyrosine kinase under hydrolytic conditions: A novel antitumour drug combination strategy 2002
 38 S7 p. S128-
1 p.
 artikel
179 Design of tumour-activated oligopeptide prodrugs that exploit the proteolytic activity of matrix metalloproteinases 2002
 38 S7 p. S121-
1 p.
 artikel
180 Detection of NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) C609T polymorphism in archived human tumour tissue using PCR-RFLP 2002
 38 S7 p. S21-
1 p.
 artikel
181 Determinants of AKT-dependent resistance to postmitochondrial apoptosis induction 2002
 38 S7 p. S166-
1 p.
 artikel
182 Development of an anti-angiogenic targeted toxin against glioblastoma multiforme 2002
 38 S7 p. S124-
1 p.
 artikel
183 Development of an Mdm2/p53 fluorescence polarization high throughput inhibitor screening assay 2002
 38 S7 p. S135-S136
2 p.
 artikel
184 Development of a sensitive and reliable LC-MS-MS assay to quantitate dimethyl benzoylphenylurea (BPU) in human plasma 2002
 38 S7 p. S41-
1 p.
 artikel
185 Development of a WT1 protein vaccine 2002
 38 S7 p. S138-
1 p.
 artikel
186 Development of high-throughput in vitro and in vivo testing strategies for the discovery of novel anticancer agents of natural origin 2002
 38 S7 p. S153-S154
2 p.
 artikel
187 Development of MMPs specific peg-peptide-doxorubicin conjugates based on angiogenesis 2002
 38 S7 p. S130-S131
2 p.
 artikel
188 Development of monoclonal antibodies targeting the uPA system for diagnosis and therapy 2002
 38 S7 p. S151-
1 p.
 artikel
189 Differential kinetic properties of monomeric and oligomeric phosphorylated c-met 2002
 38 S7 p. S97-
1 p.
 artikel
190 Discovery of gambogic acid and derivatives as apoptosis-inducing natural products with novel mechanism of action and potent in vivo anti-tumor activity 2002
 38 S7 p. S163-
1 p.
 artikel
191 Diverse and unique cellular effects of SK-7068, a novel histone deacetylase inhibitor 2002
 38 S7 p. S96-S97
2 p.
 artikel
192 17-DMAG (NSC 707545), a water-soluble geldanamycin analog, has superior in vitro and in vivo antitumor activity compared to the hsp90 inhibitor 17-AAG 2002
 38 S7 p. S60-
1 p.
 artikel
193 DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells 2002
 38 S7 p. S163-
1 p.
 artikel
194 DNA hypermethylation and resistance to chemotherapy in ovarian cancer 2002
 38 S7 p. S157-
1 p.
 artikel
195 DNA vaccines for cancer 2002
 38 S7 p. S9-S10
2 p.
 artikel
196 Dose and schedule optimization of a novel anti-angiogenic/anti-metastatic peptide, ATN-161 (Ac-PHSCN-NH2), which targets multiple fully activated integrins including alpha-5 beta-1 and alpha-v beta-3 2002
 38 S7 p. S82-
1 p.
 artikel
197 D-ring modified steroids as potent oestrone sulphatase inhibitors 2002
 38 S7 p. S123-
1 p.
 artikel
198 Drug resistance reversal — are we getting closer? 2002
 38 S7 p. S3-
1 p.
 artikel
199 DT diaphorase and cytochrome P450 reductase protein localisation in archived bladder tumour specimens: correlation with clinical response following mitomycin therapy 2002
 38 S7 p. S21-
1 p.
 artikel
200 Dynamics of tumor cell induced angiogenesis and microcirculation from tumor onset until late stage tumor disease: barriers to drug delivery 2002
 38 S7 p. S129-
1 p.
 artikel
201 Eag1 potassium channel as cancer therapy target 2002
 38 S7 p. S104-
1 p.
 artikel
202 Effect of NK1 and NK2 tachykinin receptor antagonists on the growth of human breast carcinoma cell line, MDA-MB-231 2002
 38 S7 p. S108-
1 p.
 artikel
203 EKB-569, an irreversible inhibitor of the epidermal growth factor receptor: Phase 1 trial results in patients with advanced solid tumors 2002
 38 S7 p. S64-
1 p.
 artikel
204 Elaboration of synergy between the prodrugs TST220 and TST334 and conventional chemotherapeutics 2002
 38 S7 p. S36-
1 p.
 artikel
205 Elucidation of the molecular mechanism underlying the anti-invasive activity of a novel proteasome inhibitor (Bz-Leu-Leu-Leu-COCHO) 2002
 38 S7 p. S112-
1 p.
 artikel
206 Emodin inhibits MMPs scretion and invasion in glioblastoma cells 2002
 38 S7 p. S87-
1 p.
 artikel
207 Endothelial precursor cells from human bone marrow: target for anti-angiogenesis therapy 2002
 38 S7 p. S83-
1 p.
 artikel
208 Endothelin a receptor blockade with atrasentan does not change PSA secretion in prostate cancer cell lines 2002
 38 S7 p. S111-
1 p.
 artikel
209 Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody cetuximab (IMC-C225) in combination with irinotecan (CPT-11), 5-FU, and leucovorin against human colorectal carcinoma xenografts 2002
 38 S7 p. S150-
1 p.
 artikel
210 Enhanced antitumor activity of irofulven in combination with gemcitabine against the MV522 human lung carcinoma xenograft 2002
 38 S7 p. S30-S31
2 p.
 artikel
211 Enhanced antitumor activity of TLK286 in combination with carboplatin, doxorubicin and docetaxel in human ovarian and breast cancer cell lines 2002
 38 S7 p. S35-
1 p.
 artikel
212 Enhanced DNA-directed effects of FdUMP[10] compared to 5-FU 2002
 38 S7 p. S23-S24
2 p.
 artikel
213 Enzymatic activation of prodrugs by prostate-specific membrane antigen (PSMA) 2002
 38 S7 p. S36-
1 p.
 artikel
214 Enzyme-Catalyzed Therapeutic Activation (ECTA) NB1011 (Thymectacin™) selectively targets thymidylate synthase (TS) - overexpressing tumor cells: preclinical and phase I clinical results 2002
 38 S7 p. S34-
1 p.
 artikel
215 Enzyme-mediated insolubilization therapy 2002
 38 S7 p. S36-
1 p.
 artikel
216 Epican forte - a specific formulation of nutrients containing lysine, proline, ascorbic acid, and epigallocatechin gallate inhibits matrix metalloproteinases activity and the invasion potential of human cancer cell lines 2002
 38 S7 p. S86-
1 p.
 artikel
217 Epidermal growth factor based cancer vaccine for non-small cell lung cancer therapy: report from a phase I scale up trial 2002
 38 S7 p. S137-
1 p.
 artikel
218 Epidermal growth factor inhibitors: Issues in clinical development 2002
 38 S7 p. S4-S5
2 p.
 artikel
219 Epidermal growth factor receptor (EGFR) expression on NSCLC is not useful to predict response to ZD1839 therapy: Preliminary results of the Istituto Clinico Humanitas, Rozzano, Milano 2002
 38 S7 p. S58-
1 p.
 artikel
220 Establishment of a chemotherapeutic drug/gene expression database for the molecular pharmacology of cancer 2002
 38 S7 p. S110-
1 p.
 artikel
221 Ethanolatoamine platinum chelates as prodrugs which are selectively activated in slightly acidic environment 2002
 38 S7 p. S35-S36
2 p.
 artikel
222 Evaluation in vivo of new agents for drug-resistant ovarian and breast carcinomas 2002
 38 S7 p. S130-
1 p.
 artikel
223 Evaluation of the antineoplastic properties of COX-2 selective inhibitors in human breast and prostate tumor cell lines: evidence for a COX-2 independent mechanism 2002
 38 S7 p. S85-
1 p.
 artikel
224 Evidence of variation of poly(ADP-ribose) reactions in benign and malignant prostate cell lines 2002
 38 S7 p. S27-
1 p.
 artikel
225 Examples on the role of drug administration on toxicity in mice and rats 2002
 38 S7 p. S11-
1 p.
 artikel
226 Expression of calmodulin-sensitive phosphodiesterase in rat tumour cell line and non-malignant astrocytes 2002
 38 S7 p. S104-
1 p.
 artikel
227 Expression of nuclear BCL10 is highly correlated with the expression of nuclear NF-kB and is predictive of helicobacter pylori-dependent status in early-stage high-grade gastric malt lymphoma 2002
 38 S7 p. S161-S162
2 p.
 artikel
228 Extracellular matrix of human osteosarcoma as a potential new therapeutic target 2002
 38 S7 p. S102-
1 p.
 artikel
229 Final results of a clinical and pharmacokinetic (PK) phase I study of the Raf kinase inhibitor BAY 43-9006 in refractory solid cancers: a promising anti-tumor agent 2002
 38 S7 p. S52-
1 p.
 artikel
230 Final results of a phase I study of the Raf-1 kinase inhibitor bay 43-9006 in patients with advanced refractory solid tumours 2002
 38 S7 p. S55-
1 p.
 artikel
231 Final results of the phase I study of the novel epothilone BMS-247550 administered weekly in patients (pts) with advanced solid tumors 2002
 38 S7 p. S41-
1 p.
 artikel
232 First dose in man phase I study of the anti-metastatic uPA inhibitor WX-UK1 2002
 38 S7 p. S75-S76
2 p.
 artikel
233 First results of a phase I and pharmacokinetic study of SU011248, a novel oral anti-angiogenic agent, in patients with advanced solid tumours 2002
 38 S7 p. S17-
1 p.
 artikel
234 Functional characterization of novel epidermal growth factor receptor(EGFR) and HER2 inhibitors based on pyrrolo[2,3-d]pyrimidinone structure 2002
 38 S7 p. S62-S63
2 p.
 artikel
235 Functional cloning of drug resistance genes using retroviral cDNA expression libraries 2002
 38 S7 p. S158-
1 p.
 artikel
236 Gamma-Gutamyltransferase-dependent extracellular detoxification of cisplatin by human kidney proximal tubule cells 2002
 38 S7 p. S30-
1 p.
 artikel
237 Gelsolin gene therapy using adenovirus vector for orthotopically transplanted human urinary bladder carcinoma in nude mice 2002
 38 S7 p. S146-
1 p.
 artikel
238 Gene expression microarray and 2D proteomic profiling of human ovarian adenocarcinoma cells following treatment with 17AAG, an inhibitor of the molecular chaperone Hsp90 2002
 38 S7 p. S92-S93
2 p.
 artikel
239 Gene expression profile of cisplatin resistance in ovarian cancer cell lines 2002
 38 S7 p. S158-
1 p.
 artikel
240 Gene expression profiles in rat liver slices after treatment with different hepatic tumour promotors 2002
 38 S7 p. S90-
1 p.
 artikel
241 Gene expression profiling of colorectal cancer cell lines exposed to 5-fluorouracil (5-FU) and 5-FdUrd 2002
 38 S7 p. S21-S22
2 p.
 artikel
242 Gene expression profiling of the cyclin-dependent kinase inhibitor CYC202 (R-Roscovitine) 2002
 38 S7 p. S50-
1 p.
 artikel
243 Gene expression profiling of tumor cells with varying levels of stromal involvement: a novel in vitro model for studying tumor-stroma interactions 2002
 38 S7 p. S101-
1 p.
 artikel
244 General overview of pharmacogenetics 2002
 38 S7 p. S68-
1 p.
 artikel
245 Generation and characterization of monoclonal antibodies that antagonize the binding of VEGF-C to VEGFR-3 (Flt-4) 2002
 38 S7 p. S78-
1 p.
 artikel
246 Generation of novel aclacinomycin analogues by combinatorial biosynthesis to improve antitumour properties 2002
 38 S7 p. S117-S118
2 p.
 artikel
247 Genomic-stability and growth-control mechanisms involving the p38 MAP kinase signaling pathway - identification of potential targets for cancer therapy 2002
 38 S7 p. S117-
1 p.
 artikel
248 G3139 (Genasense; Oblimersen) induces production of reactive oxygen species and hydrogen peroxide in human prostate and bladder carcinoma cells in a backbone and cpg-dependent manner 2002
 38 S7 p. S148-
1 p.
 artikel
249 Gleevec therapy in c-KIT negative soft tissue sarcomas: a molecular rationale 2002
 38 S7 p. S56-
1 p.
 artikel
250 G-quadruplex interaction of 3,6,9-trisubstituted acridines leads to specific telomerase inhibition, induction of senescence and telomere shortening 2002
 38 S7 p. S90-S91
2 p.
 artikel
251 Growth arrest, apoptosis and potentiation of 5-fluorouracil and Raltitrexed cytotoxic effect induced by histone deacetylase inhibitor SAHA in colorectal cancer cells 2002
 38 S7 p. S29-
1 p.
 artikel
252 Growth suppressive effect and apoptosis induction by N-(4-hydroxy phenyl) retinamide in human osteosarcoma cells in vitro 2002
 38 S7 p. S110-
1 p.
 artikel
253 Halofuginone activity in relation to collagen type I, VEGF and MMP-2 expression in human tumor cell lines and xenografts in vitro and in vivo 2002
 38 S7 p. S73-
1 p.
 artikel
254 Heat shock protein 27 prevents gamma radiation-induced apoptosis 2002
 38 S7 p. S145-
1 p.
 artikel
255 High-dose dexamethasone (Dex) protects against the hepatotoxicity of ET-743 in the female rat 2002
 38 S7 p. S33-
1 p.
 artikel
256 Histone deacetylase inhibitors in acute promyelocytic leukemia 2002
 38 S7 p. S115-
1 p.
 artikel
257 Histone deacetylase inhibitors potentiate breast cancer cell lines to anthracycline-induced apoptosis in a schedule and dose-dependent manner 2002
 38 S7 p. S45-
1 p.
 artikel
258 Histone methylation in transcriptional control 2002
 38 S7 p. S115-
1 p.
 artikel
259 Human Prostate Specific Membrane Antigen (PSMA) is expressed as a non-covalent dimer and provides an attractive target for cancer immunotherapy 2002
 38 S7 p. S153-
1 p.
 artikel
260 Humoral Immune Responses to MUC1 in women with BRCA1/BRCA2 mutations 2002
 38 S7 p. S136-
1 p.
 artikel
261 Hydrazones derived from monosubstitued 2-acetylpyridines and 2-hydrazino-1-methylbenzimidazole: Synthesis and biological studies 2002
 38 S7 p. S122-
1 p.
 artikel
262 Hypermethylation of RASSF1A CpG promoter region and deletion aberrations in 3p21.31 LUCA region in major epithelial tumors 2002
 38 S7 p. S93-S94
2 p.
 artikel
263 Hyperthermia and multidrug resistance: Impact on expression and regulation of MDR genes in human cancer cells 2002
 38 S7 p. S156-
1 p.
 artikel
264 Hypoxia hypersensitizes the slow-growing cells of solid tumors to glycolytic inhibitors 2002
 38 S7 p. S94-
1 p.
 artikel
265 Hypoxia increases potency of the proteasome inhibitor VELCADETM (bortezomib) for injection: potential for a hypoxic cell cytotoxin in solid tumors 2002
 38 S7 p. S166-
1 p.
 artikel
266 Identification of a new drug target using RNAi-based functional genomics 2002
 38 S7 p. S91-
1 p.
 artikel
267 Identification of a WT1 HLA A∗0201-restricted CTL epitope using whole gene in vitro priming 2002
 38 S7 p. S137-
1 p.
 artikel
268 Identification of differentially expressed proteins in cigarette smoke condensate-induced lung cancer cells by comparative proteome analysis 2002
 38 S7 p. S85-
1 p.
 artikel
269 Identification of genes associated with multiple myeloma and monoclonal gammopathy of undetermined significance using the myeloma microarray 2002
 38 S7 p. S103-
1 p.
 artikel
270 Identification of pan B-cell neoplasm markers using a combination of cDNA PCR subtraction and microarrayanalysis 2002
 38 S7 p. S149-
1 p.
 artikel
271 Identification of survivin as a transcriptional target of the Wnt pathway 2002
 38 S7 p. S162-
1 p.
 artikel
272 Identification of target tissue for glioma gene therapy by multi-tracer PET imaging 2002
 38 S7 p. S145-
1 p.
 artikel
273 Identification of tumor associated protease substrates using combinatorial chemistry 2002
 38 S7 p. S97-
1 p.
 artikel
274 IDN-5390, an orally active, antiangiogenic taxoid with low toxicity, ideally suited for metronomic dosing 2002
 38 S7 p. S37-S38
2 p.
 artikel
275 IL-7 as a therapeutic: Immunorestorative agent and vaccine adjuvant 2002
 38 S7 p. S16-S17
2 p.
 artikel
276 IL-15 mediates good and bad 2002
 38 S7 p. S17-
1 p.
 artikel
277 Image guided proteomics for molecular target discovery: a human giloma study 2002
 38 S7 p. S111-
1 p.
 artikel
278 Immunotherapy of herpesvirus reactivation 2002
 38 S7 p. S9-
1 p.
 artikel
279 Implications of N-terminal truncated p73 for cancer 2002
 38 S7 p. S94-
1 p.
 artikel
280 Inactivation of VHL gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma: MET protein as a novel target for renal carcinoma therapy 2002
 38 S7 p. S103-S104
2 p.
 artikel
281 Increased angiogenesis by bcl-2 in melanoma cells 2002
 38 S7 p. S72-
1 p.
 artikel
282 Increased ERCC1 expression predicts for improved survival in resected patients with non-small cell lung cancer (NSCLC) 2002
 38 S7 p. S15-
1 p.
 artikel
283 Increased sensitivity to chemotherapy during the window in time when tumor interstitial fluid pressure is lowered 2002
 38 S7 p. S129-S130
2 p.
 artikel
284 Indolequinone carbamate prodrugs of mustards as hypoxia-selective cytotoxins 2002
 38 S7 p. S119-S120
2 p.
 artikel
285 Influence of polysorbate 80 on unbound fractions of anticancer agents 2002
 38 S7 p. S38-
1 p.
 artikel
286 Inhibition of activated DNA transcription by Ecteinascidin 743 (ET-743) 2002
 38 S7 p. S33-
1 p.
 artikel
287 Inhibition of Akt signaling in tumor cells leads to induction of apoptosis: studies using adenovirus-mediated delivery of an Akt dominant negative mutant 2002
 38 S7 p. S95-
1 p.
 artikel
288 Inhibition of ERK phosphorylation in patients treated with the Raf kinase inhibitor BAY 43-9006 2002
 38 S7 p. S52-S53
2 p.
 artikel
289 Inhibition of lysophosphatidic acid acyltransferase-beta (LPAAT-b) by CT-32228 inhibits activation of RAS-RAF-Erk and PI3K/AKT/m-TOR pathways and selectively induces tumor cell apoptosis 2002
 38 S7 p. S90-
1 p.
 artikel
290 Inhibition of MEK/ERK and PI3K/Akt pathways blocks apoptosis suppression signaling of FLT3/ITD 2002
 38 S7 p. S166-
1 p.
 artikel
291 Inhibition of oncogenic RET signaling by Ad vector-mediated expression of a dominant-negative RET-mutant: implications for medullary thyroid cancer treatment 2002
 38 S7 p. S146-
1 p.
 artikel
292 Inhibition of PI3 kinase causes cell death through a PKB dependent mechanism and growth arrest through a PKB independent mechanism 2002
 38 S7 p. S162-
1 p.
 artikel
293 Inhibition of polo-like kinase 1 by antisense oligonucleotides and RNA interference 2002
 38 S7 p. S144-
1 p.
 artikel
294 Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation 2002
 38 S7 p. S161-
1 p.
 artikel
295 Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu 2002
 38 S7 p. S138-S139
2 p.
 artikel
296 Inhibition of tumor metastasis by ING-1(heMab), a human-engineered(TM) monoclonal antibody targeting the epithelial cell adhesion molecule 2002
 38 S7 p. S151-
1 p.
 artikel
297 Inhibition of VEGF binding to HUVEC receptors and of heparanase by the nonanticoagulant and antiangiogenic heparin derivatives ST1514 and ST2184 2002
 38 S7 p. S76-
1 p.
 artikel
298 Inhibition of VEGFR tyrosine kinase by ZK 222584/ ptk 787 (PTK/ZK) combined with fractionated radiotherapy (RT) in human squamous cell carcinoma (hSCC) in nude mice 2002
 38 S7 p. S83-
1 p.
 artikel
299 In human tumor xenografts the resistance to ET-743 or to cisplatin can be overcome by giving the two drugs in combination 2002
 38 S7 p. S34-
1 p.
 artikel
300 Insight into the mode of action of rViscumin through transcriptional profiling 2002
 38 S7 p. S98-
1 p.
 artikel
301 In silico and flexible docking screening using bioavailability, similarity and energetic filters: application to human thymidine phosphorylase 2002
 38 S7 p. S134-S135
2 p.
 artikel
302 Interactions between vinblastine and cisplatin in EAT tumours in mice: schedule dependency 2002
 38 S7 p. S39-S40
2 p.
 artikel
303 Interface of treatment and prevention research 2002
 38 S7 p. S67-
1 p.
 artikel
304 Interference with TGF-beta1 and -beta3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma 2002
 38 S7 p. S131-
1 p.
 artikel
305 Interleukin-8 (IL-8) promotes the growth of metastatic prostate cancer cells 2002
 38 S7 p. S139-
1 p.
 artikel
306 Intracellular and in vivo distribution of the pyrrolobenzodiazepine dimer SJG-136, a novel sequence-selective DNA minor groove cross-linking agent 2002
 38 S7 p. S28-S29
2 p.
 artikel
307 In vitro and in vivo characterization of a potent tyrosine kinase inhibitor that modulates angiogenesis and cancer cell proliferation 2002
 38 S7 p. S61-S62
2 p.
 artikel
308 In vitro antiangiogenic activity of thalidomide analogues 2002
 38 S7 p. S82-
1 p.
 artikel
309 In vitro pharmacological profiles and in vivo anti-angiogenesis activity of S-3304, a novel matrix metalloproteinase inhibitor 2002
 38 S7 p. S81-
1 p.
 artikel
310 In vitro studies evaluating the interaction between ZD1839 (‘Iressa’) and ionizing radiation 2002
 38 S7 p. S59-
1 p.
 artikel
311 In vivo activity of recombinant humanized monoclonal antibody 2C4 in xenografts is independent of tumor type and degree of HER2 overexpression 2002
 38 S7 p. S149-
1 p.
 artikel
312 In vivo anti-tumor efficacy of liposomal OSI-7904L in human tumor xenografts 2002
 38 S7 p. S23-
1 p.
 artikel
313 In vivo cellular and molecular multicolor imaging with GFP and RFP 2002
 38 S7 p. S102-
1 p.
 artikel
314 In vivo chamber angiogenesis assay: A simple growth factor-induced angiogenesis assay for pre-clinical screening of anti-angiogenic compounds 2002
 38 S7 p. S133-
1 p.
 artikel
315 Involvement of glutathione S-transferase pi inhibitor TLK199 in myeloproliferation and myelodifferentiation 2002
 38 S7 p. S88-S89
2 p.
 artikel
316 Involvement of proapoptotic molecules Bax and Bak in TRAIL-induced apoptosis 2002
 38 S7 p. S162-
1 p.
 artikel
317 JNK and p38 MAP kinases potentially contribute to tamoxifen resistance of breast cancer via direct phosphorylation of both estrogen receptor and AIB1 coactivator 2002
 38 S7 p. S159-
1 p.
 artikel
318 Linking genotype to phenotype: production and large scale functional analysis of gene knockouts in human cancer cells 2002
 38 S7 p. S97-
1 p.
 artikel
319 Lipid rafts as gateway for antitumor alkyl-lysophospholipids to induce apoptosis 2002
 38 S7 p. S99-
1 p.
 artikel
320 Lung cancer molecular fingerprinting: expression profiling of gene and protein with cDNA microarray and MALDI-TOF MS 2002
 38 S7 p. S100-S101
2 p.
 artikel
321 Measuring response to therapy with molecular imaging 2002
 38 S7 p. S12-
1 p.
 artikel
322 Mechanism-based high-throughput screening (HTS)for the discovery of novel anticancer drugs 2002
 38 S7 p. S134-
1 p.
 artikel
323 Mechanism of action and biomarker studies of SU11248, a selective inhibitor of split kinase domain receptor tyrosine kinases (including VEGF receptors, PDGF receptors, c-Kit, and Flt3) 2002
 38 S7 p. S61-
1 p.
 artikel
324 Mechanism of 17-B-estradiol-induced ERK1/2 activation in breast cancer cells: a role for HER2 and PKC-delta 2002
 38 S7 p. S59-S60
2 p.
 artikel
325 Mechanism of nucleotide excision repair of DNA adducts formed by chemical carcinogens and antitumor drugs 2002
 38 S7 p. S26-
1 p.
 artikel
326 Mechanisms of activation of FdUMP[10], by evaluation of intracellular thymidylate synthase inhibition in FM3A cells 2002
 38 S7 p. S23-
1 p.
 artikel
327 Mechanisms of cisplatin resistance — role of yeast SKY1 and its human homologue SRPK1 2002
 38 S7 p. S15-
1 p.
 artikel
328 β2-Microglobulin induces apoptosis in CCRF-HSB-2 leukemia cells by molecular mechanisms different than doxorubicin- and Taxol-induced apoptosis mechanisms 2002
 38 S7 p. S167-
1 p.
 artikel
329 Microsphere-encapsulated 4OH-Tamoxifen: a new sustained release delivery system with antitumour activity against DMBA-induced mammary carcinoma in sprague-dawley rats 2002
 38 S7 p. S131-
1 p.
 artikel
330 Mimotopes for high molecular weight — melanoma-associated antigen fused to albumin binding protein elicit anti-melanoma antibodies in balb/c mice 2002
 38 S7 p. S139-
1 p.
 artikel
331 Minimization of the anti-angiogenic Histidine-Proline Rich Glycoprotein (HPRG) protein 2002
 38 S7 p. S79-
1 p.
 artikel
332 Modulation of cytokine production by SRIK-NKL, a Rare CD8+ NK cell line, by hormones: implications for carcinogenesis and treatment 2002
 38 S7 p. S140-
1 p.
 artikel
333 Modulation of STAT activation by DNA damaging anti-cancer drugs 2002
 38 S7 p. S169-S170
2 p.
 artikel
334 Molecular beacon based photosensitizers for imaging guided cancer therapy 2002
 38 S7 p. S119-
1 p.
 artikel
335 Molecular class prediction of acute myeloid leukemia and myelodysplastic syndromes 2002
 38 S7 p. S92-
1 p.
 artikel
336 Molecular diagnosis of cancer by gene expression profiling 2002
 38 S7 p. S3-S4
2 p.
 artikel
337 Molecular imaging in the development of efficient gene therapy for human glioma 2002
 38 S7 p. S141-
1 p.
 artikel
338 Molecular imaging of endogenous gene expression 2002
 38 S7 p. S12-S13
2 p.
 artikel
339 Molecular modelling of quinoxaline derivatives as inhibitors of human telomerase 2002
 38 S7 p. S121-
1 p.
 artikel
340 Molecular modes of action of antimalarial artemisinin derivatives as novel anticancer drugs 2002
 38 S7 p. S99-
1 p.
 artikel
341 Monoclonal antibody against VEGFR-1 directly inhibits flt1-positive breast tumor growth 2002
 38 S7 p. S152-
1 p.
 artikel
342 Motexafin gadolinium inhibits potentially lethal damage repair in vitro and in vivo following exposure to ionizing radiation 2002
 38 S7 p. S26-
1 p.
 artikel
343 MSI derived frameshift mutations represent novel tumor specific antigens 2002
 38 S7 p. S138-
1 p.
 artikel
344 NADPH oxidase 1 (NOX 1): a novel target for colon cancer therapy 2002
 38 S7 p. S99-
1 p.
 artikel
345 Natural product-based phosphatase and tubulin-polymerisation inhibitors 2002
 38 S7 p. S14-
1 p.
 artikel
346 NCIC CTG IND.147: A first in man dose escalation and pharmacokinetic study of the novel nucleoside analog OSI-7836 given in a day 1 and 8 schedule 2002
 38 S7 p. S25-
1 p.
 artikel
347 NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines 2002
 38 S7 p. S85-
1 p.
 artikel
348 New differentiation-involution inducing agents for the treatment of breast cancer 2002
 38 S7 p. S107-
1 p.
 artikel
349 New hydrazones, a novel class of experimental antitumor agents 2002
 38 S7 p. S96-
1 p.
 artikel
350 New structural analogues of lycobetaine with high anticancer activity in vitro 2002
 38 S7 p. S44-
1 p.
 artikel
351 N-3 fatty acids improve treatment efficacy of Phor14-beta3 in nude mice with prostate cancer xenografts 2002
 38 S7 p. S105-S106
2 p.
 artikel
352 NFkappaB repression by sulfasalazine sensitizes pancreatic carcinoma cells to cytostatic drugs in vivo: a new concept of combined chemotherapy 2002
 38 S7 p. S109-
1 p.
 artikel
353 NF-kB: a factor that provides a link between stress, inflammation and cancer 2002
 38 S7 p. S116-
1 p.
 artikel
354 Non-clinical assessments of drug metabolism and pharmacokinetics of S-3304, a matrix metalloproteinase inhibitor 2002
 38 S7 p. S72-
1 p.
 artikel
355 Non-clinical assessments of safety profiles of S-3304, a matrix metalloproteinase inhibitor 2002
 38 S7 p. S76-
1 p.
 artikel
356 Non-clinical therapeutic studies of S-3304, a novel matrix metalloproteinase inhibitor 2002
 38 S7 p. S80-S81
2 p.
 artikel
357 Novel antineoplastic complexes of bismut(III), cerium(III) and lanthanum(III) 2002
 38 S7 p. S125-S126
2 p.
 artikel
358 Novel ceramide analogues display selective cytotoxicity for drug-resistant breast tumor cells over normal breast epithelial cells 2002
 38 S7 p. S108-
1 p.
 artikel
359 Novel inhibitors of MKP-1 have potent anti-cancer activity in vivo 2002
 38 S7 p. S107-
1 p.
 artikel
360 Novel mammalian chromatin reconstitution in vivo 2002
 38 S7 p. S98-
1 p.
 artikel
361 Novel nitroimidazoyluracil prodrug derivatives as tumour-selective inhibitors of the angiogenic enzyme thymidine phosphorylase 2002
 38 S7 p. S104-
1 p.
 artikel
362 Novel peptidomimetic inhibitors of Stat3 signaling and oncogenesis 2002
 38 S7 p. S98-
1 p.
 artikel
363 Novel pteridine-based inhibitors of cAMP phosphodiesterases: promising antineoplastic agents 2002
 38 S7 p. S127-
1 p.
 artikel
364 Novel recombinant Fab fragments of the TAG-72 monoclonal antibody cc49 containing an integrated radiometal binding site for radioimmunoguided surgery of DCIS 2002
 38 S7 p. S152-
1 p.
 artikel
365 Novel small molecule inhibitors of Bcl-xL anti-apoptotic proteins 2002
 38 S7 p. S14-
1 p.
 artikel
366 Novel splice variants in the ABCC1 (multidrug resistance-associated protein-1) gene in ovarian cancer 2002
 38 S7 p. S158-S159
2 p.
 artikel
367 Novel 2-step desensitization dosing regimen of intravenous PV701, an oncolytic virus, results in improved tolerability: a phase I study of patients with advanced solid tumours 2002
 38 S7 p. S155-
1 p.
 artikel
368 NQO1∗2 genotype predicts poor survival in NSCLC patients receiving radiation and chemotherapy as part of E3590 2002
 38 S7 p. S43-
1 p.
 artikel
369 Nuclear factor-kB activation. a new target for drug design? 2002
 38 S7 p. S105-
1 p.
 artikel
370 Oligonucleotide chip analysis reveals distinctive gene expression patterns in Tam-sensitive and -resistant human mammary carcinoma xenografts 2002
 38 S7 p. S159-S160
2 p.
 artikel
371 Open label phase II study on RFS 2000 in advanced/metastatic urothelial tract tumors 2002
 38 S7 p. S47-
1 p.
 artikel
372 Overexpression of the G1 domain of PG-M/Versican induces overgrowth of human leiomyosarcoma cells by altering their proliferation-apoptosis equilibrium 2002
 38 S7 p. S164-
1 p.
 artikel
373 Oxa-aza-benzo[de]anthracenes: design, synthesis and evaluation of a structurally new class of dual topoisomerase inhibitors 2002
 38 S7 p. S126-
1 p.
 artikel
374 OXI 4503 a novel vascular targeting agent: Effects on bloodflow and antitumor activity in comparison to Combretastatin A-4 phosphate 2002
 38 S7 p. S43-
1 p.
 artikel
375 Paired-box containing transcription factors as targets for therapy in solid tumors, melanomas and brain tumors 2002
 38 S7 p. S101-
1 p.
 artikel
376 Pathway pathology: how to identify signaling pathways in mouse models of human breast cancer 2002
 38 S7 p. S87-S88
2 p.
 artikel
377 PDGF receptor inhibition in tumor stroma, with STI571 or PDGF B-chain aptamers, enhances the effects of chemotherapy in experimental solid tumors by increasing tumor drug uptake 2002
 38 S7 p. S91-
1 p.
 artikel
378 P53 differential radiosensitizing mechanism of a PKC-inhibitor (PKC412) 2002
 38 S7 p. S10-S11
2 p.
 artikel
379 Pemetrexed translational research in patients with previously untreated breast cancer 2002
 38 S7 p. S25-
1 p.
 artikel
380 Peptide PNC-28 of the p53 binding domain to mdm-2 is a potent inhibitor of growth of carcinoma cells in a novel in vivo model of pancreatic carcinoma 2002
 38 S7 p. S155-
1 p.
 artikel
381 PET imaging of HSV-1 amplicon vector-mediated gene expression 2002
 38 S7 p. S144-
1 p.
 artikel
382 Phaes II study of ONYX-015 in patients with hepatobiliary tumors with p53 correlative studies 2002
 38 S7 p. S140-S141
2 p.
 artikel
383 Pharmacogenetic determinants of clinical outcome and toxicity in colon cancer 2002
 38 S7 p. S68-
1 p.
 artikel
384 Pharmacogenetic determinants of toxicity and response in acute lymphoblastic leukemia 2002
 38 S7 p. S68-S69
2 p.
 artikel
385 Pharmacogenetics of the human glutathione S-transferase P1 gene and tumor response to chemotherapy 2002
 38 S7 p. S157-S158
2 p.
 artikel
386 Pharmacogenetic variation of UDP-glucuronosyltransferases in drug resistance and cancer 2002
 38 S7 p. S68-
1 p.
 artikel
387 Pharmacogenomic expression profiling of renal cell carcinoma in a phase II trial of CCI-779: identification of surrogate markers of disease and predictors of outcome in the compartment of peripheral blood 2002
 38 S7 p. S51-
1 p.
 artikel
388 Pharmacokinetic and pharmacogenetic analysis of irinotecan (CPT-11) given in combination with R115777 2002
 38 S7 p. S44-
1 p.
 artikel
389 Pharmacokinetic/pharmacodynamic (PK/PD) relationships for the angiogenesis inhibitor ABT-510 in preclinical efficacy models 2002
 38 S7 p. S79-
1 p.
 artikel
390 Pharmacokinetics and safety of OSI-7904L (Liposomal Thymidylate Synthase Inhibitor) in patients with advanced solid tumours 2002
 38 S7 p. S23-
1 p.
 artikel
391 Pharmacokinetics of D709119 (DRH-417), a DNA minor groove-binding pyrrolobenzodiazepine monomer with a novel mechanism of action 2002
 38 S7 p. S28-
1 p.
 artikel
392 Pharmacokinetics of intrathecal partaject busulfan in a phase I trial for patients with neoplastic meningitis 2002
 38 S7 p. S28-
1 p.
 artikel
393 Pharmacokinetics of the intravenous administration of rViscumin in patients with solid tumours — First results from EORTC phase I study 16002 2002
 38 S7 p. S154-
1 p.
 artikel
394 Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study 2002
 38 S7 p. S34-
1 p.
 artikel
395 Pharmacologic characteristics of D-63153, a new potent GnRH antagonist 2002
 38 S7 p. S32-
1 p.
 artikel
396 Phase I and pharmacokinetic (PK) Trial of 3′-C-ethylnylcytidine (TAS-106) in solid tumors 2002
 38 S7 p. S108-
1 p.
 artikel
397 Phase I and pharmacokinetics trial of BNP7787 in patients receiving cisplatin and paclitaxel for advanced Non-Small Cell Lung Cancer (NSCLC) 2002
 38 S7 p. S48-
1 p.
 artikel
398 Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced malignancies 2002
 38 S7 p. S42-
1 p.
 artikel
399 Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPAR gamma) 2002
 38 S7 p. S89-
1 p.
 artikel
400 Phase I and pharmacokinetic study of oral irinotecan (CPT-11) on a daily-times 5 schedule every 3 weeks in combination with evaluation of food effect 2002
 38 S7 p. S46-
1 p.
 artikel
401 Phase I and pharmacokinetic study (PK) of the combination of multitargeted antifolate pemetrexed (ALIMTA) with irinotecan (CPT-11) in patients with advanced malignancies 2002
 38 S7 p. S24-S25
2 p.
 artikel
402 Phase I and pharmacokinetic trial of ILY293111 in combination with gemcitabine 2002
 38 S7 p. S89-
1 p.
 artikel
403 Phase I and pharmacologic study of diflomotecan (BN80915) administered intravenously daily for 5 consecutive days every 3 weeks in patients with solid tumors 2002
 38 S7 p. S46-
1 p.
 artikel
404 Phase I and pharmacologic study of the macromolecular topoisomerase-I-inhibitor DE-310 given once every 2 or 6 weeks in patients with solid tumors 2002
 38 S7 p. S45-
1 p.
 artikel
405 Phase I, bioavailability, and pharmacokinetic study of oral dosage of CCI-779 administered to patients with advanced solid malignancies 2002
 38 S7 p. S54-
1 p.
 artikel
406 Phase I clinical trials with direct intratumoural injection of an adenovirus-nitroreductase (Ad-NTR) vector, CTL102, in liver and prostate tumour patients 2002
 38 S7 p. S142-
1 p.
 artikel
407 Phase I dose-escalating trial of KOS-862 (epothilone D) in patients with advanced malignancies 2002
 38 S7 p. S41-
1 p.
 artikel
408 Phase I/II study of CT-2103 (Xyotax) in patients with recurrent ovarian cancer 2002
 38 S7 p. S130-
1 p.
 artikel
409 Phase II study of E7070 in patients with metastatic melanoma (stage IV) 2002
 38 S7 p. S50-
1 p.
 artikel
410 Phase II Study of first-line chemotherapy using CT-2103 in patients with Non-Small-Cell Lung Cancer who are > or = 70 years of age or who have PS = 2 2002
 38 S7 p. S130-
1 p.
 artikel
411 Phase II study of OSI-774 in patients with metastatic colorectal cancer 2002
 38 S7 p. S57-
1 p.
 artikel
412 Phase II study of the DNA methyltransferase I (DNMT1) inhibitor MG98 in patients (pts) with renal cell carcinoma (RCC). A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) 2002
 38 S7 p. S141-
1 p.
 artikel
413 Phase II Study of TLK286 (Glutathione Analog Activated by GST P1-1) in refractory colorectal cancer 2002
 38 S7 p. S35-
1 p.
 artikel
414 Phase II study of Xyotax (CT-2103) in patients with colorectal cancer having recurrent disease after treatment with a 5-fluorouracil-containing regimen 2002
 38 S7 p. S132-
1 p.
 artikel
415 Phase II trial of edatrexate in adult patients with metastatic soft tissue sarcomas, an Eastern Cooperative Oncology Group (ECOG) final report 2002
 38 S7 p. S24-
1 p.
 artikel
416 Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 (Erlotinib or Tarceva) in combination with docetaxel 2002
 38 S7 p. S53-
1 p.
 artikel
417 Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies 2002
 38 S7 p. S54-
1 p.
 artikel
418 Phase I safety, pharmacokinetic and pharmacodynamic study of recombinant human anti-VEGF antibody HuMV833 in patients with advanced cancer 2002
 38 S7 p. S80-
1 p.
 artikel
419 Phase I study of an all-oral combination of vinorelbine (VRL) and cyclophosphamide (Ctx) as second line treatment in patients with metastatic breast cancer (MBC) 2002
 38 S7 p. S42-
1 p.
 artikel
420 Phase I study of flavopiridol (HMR1275) in combination with paclitaxel and carboplatin in non-small cell lung cancer (NCSLC) patients 2002
 38 S7 p. S49-S50
2 p.
 artikel
421 Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with previously untreated extensive stage small cell lung cancer 2002
 38 S7 p. S147-S148
2 p.
 artikel
422 Phase I study of oral gallium maltolate in patients with refractory malignancies 2002
 38 S7 p. S48-
1 p.
 artikel
423 Phase I study of Xyotax (CT-2103) and carboplatin in patients with solid tumors: preliminary data 2002
 38 S7 p. S132-
1 p.
 artikel
424 Phase I study of Xyotax (CT-2103) and cisplatin in patients with solid tumors: preliminary data 2002
 38 S7 p. S132-
1 p.
 artikel
425 Phase I study to determine the safety of MS209 in combination with docetaxel in patients with solid progressive tumor 2002
 38 S7 p. S155-S156
2 p.
 artikel
426 Phase I trial of recombinant human endostatin (rHu-endo) administered by continuous infusion (CI) intravenously (IV) in patients with solid tumors: a preliminary report 2002
 38 S7 p. S73-S74
2 p.
 artikel
427 Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) in patients with non-small cell lung cancer who failed prior platinum-based regimens 2002
 38 S7 p. S36-S37
2 p.
 artikel
428 Phase 2 Study of TLK286 (GST P1-1 Activated Glutathione Analog) in patients with platinum and paclitaxel refractory/resistant advanced epithelial ovarian cancer 2002
 38 S7 p. S34-S35
2 p.
 artikel
429 Phosphorylation on Tyrosine-15 of p34Cdc2 by ErbB2 receptor tyrosine kinase inhibits p34Cdc2 activation and is involved in resistance to taxol-induced apoptosis 2002
 38 S7 p. S161-
1 p.
 artikel
430 Pifithrin alpha and beta do not inhibit ionising radiation dependent p53 responses in human wild type p53 ovarian and colon cell lines 2002
 38 S7 p. S160-
1 p.
 artikel
431 Pilot studies of antimetabolites preceeded by irinotecan in advanced solid tumors 2002
 38 S7 p. S44-S45
2 p.
 artikel
432 Polo-like kinases and mitotic control 2002
 38 S7 p. S116-
1 p.
 artikel
433 Polymorphisms of MDR1 and MRP2/cMOAT in healthy North Eastern Italian subjects 2002
 38 S7 p. S156-
1 p.
 artikel
434 Post-irradiation carbogen breathing enhances the effectiveness of the bioreductive anticancer drug tirapazamine in SiHa but not SCCVII tumours in mice — a drug penetration phenomenon 2002
 38 S7 p. S132-
1 p.
 artikel
435 Potentiation of topoisomerase II poison cytotoxicity in the K562 human leukaemia cell line by the novel DNA-dependent protein kinase inhibitor NU7026 2002
 38 S7 p. S26-
1 p.
 artikel
436 Potent in vivo activity of MCR peptides against chemotherapy-resistant human small cell lung cancer (SCLC) 2002
 38 S7 p. S62-
1 p.
 artikel
437 PPARgamma ligands modulate PPARgamma and RARbeta expression in human glioblastoma cell lines 2002
 38 S7 p. S109-S110
2 p.
 artikel
438 Preclinical activity against liver metastases of Nemorubicin, a DNA-intercalating cytotoxic agent for the treatment of hepatocellular carcinoma 2002
 38 S7 p. S19-
1 p.
 artikel
439 Preclinical and clinical toxicity correlations for cancer drugs developed by the NCl 2002
 38 S7 p. S12-
1 p.
 artikel
440 Preclinical efficacy evaluation of MLN2704: A chemotherapeutic-monoclonal antibody conjugate targeting prostate-specific membrane antigen (PSMA) 2002
 38 S7 p. S150-
1 p.
 artikel
441 Preclinical efficacy, toxicology and pharmacokinetics of NVP-LAQ824, a novel synthetic histone deacetylase inhibitor 2002
 38 S7 p. S98-S99
2 p.
 artikel
442 Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503 2002
 38 S7 p. S39-
1 p.
 artikel
443 Preclinical evaluation of the tyrosine kinase inhibitor SU11248 for the treatment of breast cancer 2002
 38 S7 p. S75-
1 p.
 artikel
444 Preclinical rationale for a combined treatment with irinotecan and the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) in irinotecan-refractory human colon cancer 2002
 38 S7 p. S157-
1 p.
 artikel
445 Pre-clinical studies of concomitant PS-341 and ionizing radiation therapy: Local and systemic anti-tumor effects 2002
 38 S7 p. S16-
1 p.
 artikel
446 Preliminary results from a Phase II trial of EPO906 in patients with advanced refractory ovarian cancer 2002
 38 S7 p. S43-
1 p.
 artikel
447 Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies 2002
 38 S7 p. S49-
1 p.
 artikel
448 Probing the role of JNK in transformed cell proliferation and survival 2002
 38 S7 p. S106-
1 p.
 artikel
449 Product development of fenretinide, NSC 374551, intravenous formulation 2002
 38 S7 p. S21-
1 p.
 artikel
450 Prognostic and predictive value of vascular endothelial growth factor (VEGF) in patients with non small cell lung cancer (NSCLC) 2002
 38 S7 p. S77-S78
2 p.
 artikel
451 Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma 2002
 38 S7 p. S110-
1 p.
 artikel
452 Progress in chemoprevention of breast cancer 2002
 38 S7 p. S67-
1 p.
 artikel
453 Prolonged antigen presentation of monocyte-derived dendritic cells loaded with plga-microspheres 2002
 38 S7 p. S136-
1 p.
 artikel
454 Properties of the new anthracycline derivative containing modified daunosamine moiety 2002
 38 S7 p. S19-S20
2 p.
 artikel
455 Prospective identification and isolation of breast cancer tumor initiating cells 2002
 38 S7 p. S104-
1 p.
 artikel
456 Prospective phase I/II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix 2002
 38 S7 p. S160-
1 p.
 artikel
457 Protein expression and tumor hypoxia 2002
 38 S7 p. S10-
1 p.
 artikel
458 Protein phosphatase 2A, a novel and unexplored anticancer target 2002
 38 S7 p. S94-
1 p.
 artikel
459 Proteolysis of xyotax by lysosomal cathepsin B; metabolic profiling in tumor cells using LC-MS 2002
 38 S7 p. S129-
1 p.
 artikel
460 PTEN suppresses hyaluronic acid induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation 2002
 38 S7 p. S80-
1 p.
 artikel
461 PX-478, a potent inhibitor of hypoxia-inducible factor-1 (HIF-1) and antitumor agent 2002
 38 S7 p. S90-
1 p.
 artikel
462 Quadruplex formation in the c-MYC promoter inhibits protein binding and correlates with in vivo promoter activity 2002
 38 S7 p. S106-S107
2 p.
 artikel
463 Quantitative analysis of p53 targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo 2002
 38 S7 p. S146-
1 p.
 artikel
464 Radiation and the endothelium: the importance and the modulatory effects of VEGF, bFGF, alphavbeta3 and the extracellular matrix components on ionizing radiation-induced endothelial cell damage 2002
 38 S7 p. S74-
1 p.
 artikel
465 Radiosensitisation of cultured cells by brostallicin — a brominated minor groove binding DNA ligand 2002
 38 S7 p. S27-
1 p.
 artikel
466 Rapamycin, an inhibitor of mTOR, reverses chemoresistance in PTEN negative prostate cancer xenografts 2002
 38 S7 p. S159-
1 p.
 artikel
467 Rapamycin enhances radiation-induced apoptosis in human glioma cells with constitutive activation of the PI3K/PKB signalling pathway 2002
 38 S7 p. S58-
1 p.
 artikel
468 Rapid and complete thymidylate synthase (TS) inhibition in tumors after fluorouracil (5-FU) by methylene-tetrahydrofolate (ch2fh4) preloading 2002
 38 S7 p. S22-
1 p.
 artikel
469 Ras and Rho GTPases: targets of FTase and GGTase I inhibitors for cancer treatment? 2002
 38 S7 p. S100-
1 p.
 artikel
470 Regulation and function of Cyclooxygenase-2 (COX-2) in ovarian carcinoma cells 2002
 38 S7 p. S86-
1 p.
 artikel
471 Regulation of Bcl-2 family members during drug-induced apoptosis 2002
 38 S7 p. S14-S15
2 p.
 artikel
472 Regulation of genomic instability in early breast cancer 2002
 38 S7 p. S117-
1 p.
 artikel
473 Relationships between DNA alkylation, perturbation of the cell cycle and cytotoxicity in a series of benzoacronycine derivatives 2002
 38 S7 p. S127-
1 p.
 artikel
474 Release of GST-pi promoter hypermethylation and activity of brostallicin in human prostate cancer cells 2002
 38 S7 p. S31-
1 p.
 artikel
475 Research and identification of polymorphic variants of the gene of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38 2002
 38 S7 p. S44-
1 p.
 artikel
476 Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFr) monoclonal antibody emd 72000 in patients with EGFr expressing solid tumors 2002
 38 S7 p. S53-
1 p.
 artikel
477 Retained sensitivity to brostallicin after loss of DNA mismatch repair 2002
 38 S7 p. S155-
1 p.
 artikel
478 Rhythms in BCL-2, cell cycle distribution and circadian clock gene expression in normal tissues and in tumor for improving novel targeted cancer therapy 2002
 38 S7 p. S169-
1 p.
 artikel
479 Ribozyme-PEI complex technology allows efficient down-regulation of gene expression in vitro and in vivo 2002
 38 S7 p. S146-
1 p.
 artikel
480 Risk targeting and strategy for chemoprevention of head and neck cancer 2002
 38 S7 p. S84-
1 p.
 artikel
481 Role of ld proteins in tumor angiogenesis 2002
 38 S7 p. S75-
1 p.
 artikel
482 Role of MAPKs in heat-induced apoptosis 2002
 38 S7 p. S165-
1 p.
 artikel
483 Roles of oncogenes and tumor suppressor genes in apoptosis 2002
 38 S7 p. S15-
1 p.
 artikel
484 SELDI-TOF proteomic patterns of human and experimental brain tumors: potential for new biomarkers and for pharmaco-proteomic endpoints in anti-angiogenic therapy 2002
 38 S7 p. S73-
1 p.
 artikel
485 Signal therapy of RAS cancers by blocking PAK pathways 2002
 38 S7 p. S93-
1 p.
 artikel
486 Smac agonists sensitize for TRAIL- or anticancer drug-induced apoptosis and induce eradication of malignant glioma in vivo 2002
 38 S7 p. S164-
1 p.
 artikel
487 Small molecule inhibitors of BCL-2 protein-protein interactions show anti-tumor activity in nude mice 2002
 38 S7 p. S163-
1 p.
 artikel
488 Somatostatin modulates Ku 70/86 DNA binding activity 2002
 38 S7 p. S27-
1 p.
 artikel
489 Specific inhibition of bcr-abl gene expression by small interfering RNA in bcr-abl+ cells 2002
 38 S7 p. S143-
1 p.
 artikel
490 Specific inhibition of the growth-associated alpha isoform of topoisomerase II by the novel anticancer triazoloacridone C-1305 2002
 38 S7 p. S45-
1 p.
 artikel
491 STAT5a is activated in human breast cancers and associates with the p85 subunit of PI3 kinase 2002
 38 S7 p. S164-
1 p.
 artikel
492 Strategies to optimise anti-EGF receptor therapies 2002
 38 S7 p. S4-
1 p.
 artikel
493 Structural consequences of trans-membrane association and mechanism of molecular recognition at the active site of human estrone sulfatase, a potential target for hormonal breast cancer therapy 2002
 38 S7 p. S135-
1 p.
 artikel
494 Structure-Activity-Relationship (SAR) study of novel C2/C3-unsaturated C2-aryl-substituted pyrrolobenzodiazepine monomer antitumour agents 2002
 38 S7 p. S122-
1 p.
 artikel
495 Structure-activity relationships of oxalatoplatinum(II) complexes: identification of oxaliplatin derivatives with improved activity 2002
 38 S7 p. S29-
1 p.
 artikel
496 Structure-activity relationships of platinum(II) phosphonate compounds for the treatment of bone malignancies 2002
 38 S7 p. S29-S30
2 p.
 artikel
497 Structure-based design and optimisation of substituted 2-phenylamino-4-(thiazol-5-yl)-pyrimidine CDK inhibitors 2002
 38 S7 p. S124-
1 p.
 artikel
498 Structure-growth regulatory potency relationship investigation of TIMP-1 (tissue inhibitor of metalloproteinases) C-terminal domain fragments 2002
 38 S7 p. S74-
1 p.
 artikel
499 Studies on the cellular uptake and cleavage of nucleoside analogues conjugated to motexafin gadolinium 2002
 38 S7 p. S118-S119
2 p.
 artikel
500 SU11248 and STI-571, small molecule inhibitors of Kit and PDGFR inhibit growth of SCLC preclinical models 2002
 38 S7 p. S80-
1 p.
 artikel
501 Suppression of microtubule dynamic instability by discodermolide in living non-small cell lung carcinoma cells and its synergy with paclitaxel 2002
 38 S7 p. S38-
1 p.
 artikel
502 Surrogate endpoint biomarkers in chemopreventive agent development 2002
 38 S7 p. S67-
1 p.
 artikel
503 Sustained activation of JNK cascade and apoptosis induced by rapamycin is suppressed by p53 2002
 38 S7 p. S70-
1 p.
 artikel
504 Synergistic therapy of head and neck cancer with EGFR blockade and paclitaxel is mediated through abrogation of PI3kinase/AKT signaling 2002
 38 S7 p. S166-S167
2 p.
 artikel
505 Synthesis and biological evaluation of phosphoramide mustard (PM) prodrugs 2002
 38 S7 p. S127-S128
2 p.
 artikel
506 Synthesis and evaluation of renal dipeptidase inhibitors as biomarkers for colon cancer 2002
 38 S7 p. S126-
1 p.
 artikel
507 Synthesis, structure and anticancer activity of a novel platinum(II) coordination compound of 4-aminosalicylic acid 2002
 38 S7 p. S135-
1 p.
 artikel
508 Targeting a protein tyrosine phosphatase, PRL-1, for the treatment of pancreatic cancer 2002
 38 S7 p. S106-
1 p.
 artikel
509 Targeting C/EBP alpha in leukemia and lung cancer 2002
 38 S7 p. S70-
1 p.
 artikel
510 Targeting Jak3 with small molecules to inhibit T-cell activity 2002
 38 S7 p. S105-
1 p.
 artikel
511 Targeting mitochondria for apoptosis induction 2002
 38 S7 p. S14-
1 p.
 artikel
512 Targeting of phosphatases (PTPases) by sodium stibogluconate (SSb) in WM-9 human melanoma for potentiation of Stat-1 phosphorylation and for antitumor effects 2002
 38 S7 p. S103-
1 p.
 artikel
513 Taxane-monoclonal antibody covalent conjugates for targeted chemotherapy of cancer 2002
 38 S7 p. S128-S129
2 p.
 artikel
514 Telomestatin has a mixed type of binding modes with G-quadruplexes: intercalation between G-tetrads and end-stacking in the loop regions of intramolecular G-quadruplexes 2002
 38 S7 p. S89-
1 p.
 artikel
515 TGF-beta activated Smad and p38 signaling pathways are important mediators of antiestrogen action in breast cancer cells 2002
 38 S7 p. S32-
1 p.
 artikel
516 Thalidomide modulation of Irinotecan; an NF-kB dependent effect? 2002
 38 S7 p. S53-
1 p.
 artikel
517 The Adverse Event Expedited Reporting System (AdEERS) of the cancer therapy evaluation program 2002
 38 S7 p. S64-
1 p.
 artikel
518 The alpha-v beta-3 antagonist S-247 inhibits the growth of primary renal tumor and spontaneous lung metastases in the RENCA model 2002
 38 S7 p. S74-
1 p.
 artikel
519 The angiogenic factor CYR61, a downstream effector of heregulin, protects breast cancer cells from paclitaxel-induced cell death through integrin alphav beta3 2002
 38 S7 p. S108-S109
2 p.
 artikel
520 The antitumor activities of celecoxib are mediated primarily through inhibition of pge2 production 2002
 38 S7 p. S71-
1 p.
 artikel
521 The antitumor activity of OSI-7836 (GS7836, 4′-thio-araC), a nucleoside analog, in combination with cisplatin in human NSCLC xenografts in mice 2002
 38 S7 p. S24-
1 p.
 artikel
522 The cancer therapy evaluation program initiatives for enhancing industry collaborations 2002
 38 S7 p. S64-
1 p.
 artikel
523 The chemopreventive activities of farnesol and geraniol in rats submitted to the resistant hepatocyte model of hepatocarcinogenesis involve inhibition of cell proliferation 2002
 38 S7 p. S87-
1 p.
 artikel
524 The chemopreventive activities of vitamin A, beta-carotene and all-trans and 9-cis retinoic acids during hepatocarcinogenesis in rats involve inhibition of cell proliferation but not induction of apoptosis 2002
 38 S7 p. S86-S87
2 p.
 artikel
525 The combination of nemorubicin with cisplatin and mitomycin C is synergistic in experimental tumor models 2002
 38 S7 p. S20-
1 p.
 artikel
526 The cyclin-dependent kinase inhibotor cyc202 is effective in human leiomyosarcoma (LMS) cell lines in combination with doxorubicin 2002
 38 S7 p. S111-
1 p.
 artikel
527 The cytotoxic effects of the anticancer drugs rviscumin and paclitaxel are dependent on cellular HER-2 (c-erbB2/neu) levels 2002
 38 S7 p. S168-
1 p.
 artikel
528 The effect of human recombinant endostatin (rh-Endo) on blood flow and glucose metabolism in normal tissues 2002
 38 S7 p. S72-
1 p.
 artikel
529 The effect of MDR1 on the ex vivo activity of XR5944 (MLN944) and XR11576 (MLN576), two novel DNA targeting agents 2002
 38 S7 p. S32-
1 p.
 artikel
530 The effect of nitric oxide on cyclooxygenase-2 expression is mediated through the activation of guanylate cyclase in head and neck cancer cell lines 2002
 38 S7 p. S76-
1 p.
 artikel
531 The follicular thyroid carcinoma associated PAX8/PPAR-gamma-1 fusion gene permits anchorage independent growth in a follicular thyroid cell line 2002
 38 S7 p. S95-
1 p.
 artikel
532 The forced reexpression of the keratin 18 gene in human breast cancer cells results in redifferentiation and a dramatic drop in malignancy 2002
 38 S7 p. S88-
1 p.
 artikel
533 The histone deacetylase inhibitor LAQ824 is selectively toxic to tumor cell lines including multidrug resistant cells 2002
 38 S7 p. S103-
1 p.
 artikel
534 The impact of c-Src on drug sensitivity/resistance in human colon cancer cells 2002
 38 S7 p. S165-S166
2 p.
 artikel
535 The intravenous administration of rViscumin induces cytokine release and antibody formation. Results of EORTC New Drug Development Group trial 16002 2002
 38 S7 p. S154-
1 p.
 artikel
536 The mTOR inhibitor, CCI-779, restores tamoxifen response in breast cancer cells with high Akt activity 2002
 38 S7 p. S158-
1 p.
 artikel
537 The novel vascular-targeting agent ZD6126 shows enhanced anti-tumour efficacy in large, bulky tumours 2002
 38 S7 p. S40-
1 p.
 artikel
538 The potential role of STI 571 in the treatment of head and neck cancer 2002
 38 S7 p. S63-
1 p.
 artikel
539 The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML cells expressing a constitutively activated FLT3 2002
 38 S7 p. S83-S84
2 p.
 artikel
540 The role of Chk1 signaling pathways in response to the topoisomerase I poison SN-38 2002
 38 S7 p. S134-
1 p.
 artikel
541 The role of G1 and G2 checkpoint control proteins involved in cell cycle arrest following treatment with the HSP90 inhibitor 17AAG 2002
 38 S7 p. S60-
1 p.
 artikel
542 The role of poly(ADP-ribose) polymerase-1 (PARP-1) in the cellular response to topoisomerase I poisons 2002
 38 S7 p. S69-
1 p.
 artikel
543 The role of secondary DNA structures in silencing transcription 2002
 38 S7 p. S115-
1 p.
 artikel
544 The seco-taxane IDN5390 is able to circumvent paclitaxel resistance in drug-resistant cells with overexpression of class III beta-tubulin 2002
 38 S7 p. S37-
1 p.
 artikel
545 The silybin-phospholipid complex IdB 1016 inhibits human ovarian cancer growth in athymic nude mice 2002
 38 S7 p. S154-
1 p.
 artikel
546 The synthesis and biological evaluations of n-aminotetrahydropyridines as anticancer agents 2002
 38 S7 p. S126-S127
2 p.
 artikel
547 The synthesis of hypoxia-selective nitroaromatic compounds as bioreductive drug delivery agents 2002
 38 S7 p. S120-
1 p.
 artikel
548 The transcription factor Egr-1 promotes prostate carcinoma and systemic treatment of TRAMP mice with antisense Egr-1 inhibits tumour formation 2002
 38 S7 p. S92-
1 p.
 artikel
549 The unfolded protein response pathway plays a key role in anti-cancer drug sensitivity 2002
 38 S7 p. S91-
1 p.
 artikel
550 The use of in vitro bone marrow toxicity to predict clinical MTD in humans 2002
 38 S7 p. S11-
1 p.
 artikel
551 The use of predicting factors and surrogate markers in breast cancer biopsies treated with targeted erbB tyrosine kinase inhibitor 2002
 38 S7 p. S57-S58
2 p.
 artikel
552 TNFerade, an adenovector encoding the human tumor necrosis factor alpha gene, in soft tissue sarcoma in the extremity. safety and early efficacy data 2002
 38 S7 p. S141-S142
2 p.
 artikel
553 TNF revisted: New perspectives for a successful antivascular cancer therapy 2002
 38 S7 p. S17-
1 p.
 artikel
554 Topoisomerases and transcriptional regulation 2002
 38 S7 p. S71-
1 p.
 artikel
555 TP53 status may predict pathological complete remission (pCR) to cisplatin + fluorouracil + leucovorin (PFL) in ethmoidal intestinal type adenocarcinoma (ITAC) treated with preoperative chemotherapy 2002
 38 S7 p. S22-
1 p.
 artikel
556 Transcriptional profile of response during senescence or apoptosis of colon carcinoma cells after SN-38 treatment 2002
 38 S7 p. S16-
1 p.
 artikel
557 Transcriptional response to ionizing radiation (IR) in normal and tumor cells 2002
 38 S7 p. S161-
1 p.
 artikel
558 Transfection of follicular thyroid cancer cells with thyrotropin receptor cDNA alleviates malignant phenotype in vitro and in vivo 2002
 38 S7 p. S88-
1 p.
 artikel
559 Transmembrane inhibitors of ABC transporters 2002
 38 S7 p. S120-
1 p.
 artikel
560 Triapine, a ribonucleotide reductase inhibitor, enhances incorporation of gemcitabine into DNA and cytotoxicity to KB cells 2002
 38 S7 p. S26-
1 p.
 artikel
561 Tumor genotype, RRM1 expression, and outcome of patients with lung cancer 2002
 38 S7 p. S82-S83
2 p.
 artikel
562 Tumor necrosis alpha (TNFa) blockade as an adjunct to dose intense chemotherapy 2002
 38 S7 p. S140-
1 p.
 artikel
563 Tumor-selective toxicity of histone deacetylase inhibitors is due to their targeting cell cycle checkpoint points 2002
 38 S7 p. S95-
1 p.
 artikel
564 Tumor suppressor genes in chromosome 3p21.31 2002
 38 S7 p. S92-
1 p.
 artikel
565 Tumour associated cellular and molecular changes induced in endothelial cells 2002
 38 S7 p. S84-
1 p.
 artikel
566 Two photoaffinity analogs of HTI-286, a synthetic analog of hemiasterlin, interact with alpha-tubulin 2002
 38 S7 p. S119-
1 p.
 artikel
567 Update on tyrosine kinase inhibitors 2002
 38 S7 p. S4-
1 p.
 artikel
568 Use of a novel, hepatocyte growth factor-induced transcript, Mig-7, as a marker for circulating and migrating cancer cells 2002
 38 S7 p. S83-
1 p.
 artikel
569 Use of OvaRex(r) MAb-b43.13 as an immunotherapeutic treatment of epithelial ovarian cancer: experience as single agent post first-line therapy and in combination with chemotherapy in recurrent disease 2002
 38 S7 p. S137-
1 p.
 artikel
570 Validation of reliable assay methods for glutathione quantitation and glutathione s-transferase activity in cancer patients 2002
 38 S7 p. S109-
1 p.
 artikel
571 Value of human tumor xenograft models for predicting pharmacodynamic and toxicological endpoints in preclinical development of molecular drugs 2002
 38 S7 p. S11-
1 p.
 artikel
572 Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nude mouse model 2002
 38 S7 p. S40-
1 p.
 artikel
573 VEGF-Trap: a novel, potent VEGF blocker with anti-tumor effects 2002
 38 S7 p. S82-
1 p.
 artikel
574 What new pharmacokinetic information can molecular imaging provide us 2002
 38 S7 p. S12-
1 p.
 artikel
575 What the pharmaceutical industry wants from new imaging technologies for drug development 2002
 38 S7 p. S13-
1 p.
 artikel
576 WP744, a novel anthracycline highly active against STI-571-resistant tumors 2002
 38 S7 p. S126-
1 p.
 artikel
577 ZD4054: a specific endothelin A receptor antagonist with potential utility in prostate cancer and metastatic bone disease 2002
 38 S7 p. S102-
1 p.
 artikel
578 ZD1839 (‘Iressa’) improves the antitumour activity of tamoxifen (‘Nolvadex’) and ICI 182, 780 (‘Faslodex’) in antihormone responsive breast cancer 2002
 38 S7 p. S59-
1 p.
 artikel
579 ZD1839 (‘Iressa’) provides clinically significant antitumor activity and improves disease-related symptoms in pretreated patients with advanced non-small-cell lung cancer (NSCLC): results of two Phase II trials (IDEAL 1 and IDEAL 2) 2002
 38 S7 p. S56-S57
2 p.
 artikel
                             579 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland